Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Clinical significance of the ReNeu trial in NF1- associated plexiform neurofibroma

Christopher Moertel • 31 May 2024
ASCO 2024
Neuroendocrine Tumor Mirdametinib
ReNeu

Christopher Moertel, MD, University of Minnesota, Minneapolis, MN, highlights the clinical significance of the Phase IIb ReNeu trial (NCT03962543), which assessed mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN). Clinically meaningful responses, such as pain management, were observed, especially in adults, who previously had no approved treatments. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employment – OX2 Therapeutics
Leadership – OX2 Therapeutics
Stock and Other Ownership Interests – OX2 Therapeutics
Consulting or Advisory Role – Alexion Pharmaceuticals
Patents, Royalties, Other Intellectual Property – OX2 Therapeutics
Travel, Accommodations, Expenses – Alexion Pharmaceuticals

More from Christopher Moertel

ReNeu: mirdametinib in NF1-associated symptomatic inoperable plexiform neurofibroma
1:14
ReNeu: mirdametinib in NF1-associated symptomatic inoperable plexiform neurofibroma
Christopher Moertel • 31 May 2024
Key unmet needs in the treatment of neurofibromatosis-associated PN
1:11
Key unmet needs in the treatment of neurofibromatosis-associated PN
Christopher Moertel • 31 May 2024

Related Videos

Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs
2:17
Oncolytic virus SVV-001 plus nivolumab and ipilimumab in high-grade NENs
Chinmay Jani • 31 May 2026
Gastroenteropancreatic neuroendocrine tumors and liver metastases in China
6:17
Gastroenteropancreatic neuroendocrine tumors and liver metastases in China
Chunhui Yuan • 6 Nov 2025
177Lu-DOTATATE improves outcomes in advanced GEP-NETs versus octreotide
2:05
177Lu-DOTATATE improves outcomes in advanced GEP-NETs versus octreotide
Stephen Lam Chan • 16 Dec 2025
Improving diagnosis & treatment selection in grade 3 neuroendocrine tumors
2:26
Improving diagnosis & treatment selection in grade 3 neuroendocrine tumors
Mairead McNamara • 20 Oct 2025
The content of VJOncology is intended for healthcare professionals